These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12599844)

  • 1. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S;
    Lancet; 2002 Mar; 359(9311):1004-10. PubMed ID: 11937179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
    Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.
    Mangano DT; Layug EL; Wallace A; Tateo I
    N Engl J Med; 1996 Dec; 335(23):1713-20. PubMed ID: 8929262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 9. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
    Lindholm LH; Ibsen H; Borch-Johnsen K; Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristianson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman JM; Snapinn S;
    J Hypertens; 2002 Sep; 20(9):1879-86. PubMed ID: 12195132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
    Vulpis V; Antonacci A; Prandi P; Bokor D; Pirrelli A
    Minerva Med; 1991 Apr; 82(4):189-93. PubMed ID: 1673233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
    Diabet Med; 2002 Sep; 19 Suppl 5():6. PubMed ID: 12207800
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
    Park JB; Intengan HD; Schiffrin EL
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Fuchs FD
    Lancet; 2002 Jun; 359(9324):2203; author reply 2203-4. PubMed ID: 12091010
    [No Abstract]   [Full Text] [Related]  

  • 16. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
    Heinzl S
    Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
    [No Abstract]   [Full Text] [Related]  

  • 17. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hamon M
    Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
    Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Hypertension; 1998 Dec; 32(6):989-97. PubMed ID: 9856962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
    González-Juanatey JR
    Rev Esp Cardiol; 2002 Sep; 55(9):887-94. PubMed ID: 12236916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
    Scheen AJ
    Rev Med Liege; 2002 Apr; 57(4):240-4. PubMed ID: 12073799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.